Ginsenoside Rk1 induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• Ginsenoside Rk1 (Rk1) possesses known anti-inflammatory and anti-cancer properties.
• Limited research exists on Rk1's efficacy against triple-negative breast cancer (TNBC).

Purpose of the Study:

• To investigate the anti-proliferative effects of Rk1 on MDA-MB-231 TNBC cells.
• To elucidate the underlying mechanisms of Rk1's action in TNBC.

Main Methods:

• In vitro studies using MDA-MB-231 cells to assess proliferation, colony formation, LDH release, and cell cycle.
• In vivo xenograft model to evaluate tumor growth inhibition and organ toxicity.
• Western blot analysis to examine apoptosis-related proteins and signaling pathways (PI3K/Akt).
• Experiments involving caspase inhibitors, insulin, and N-acetylcysteine (NAC) to confirm pathway involvement.

Main Results:

• Rk1 significantly suppressed tumor growth in vivo with minimal organ toxicity.
• Rk1 inhibited cell proliferation, colony formation, induced LDH release, and caused G0/G1 cell cycle arrest.
• Rk1 triggered reactive oxygen species (ROS) generation, reduced mitochondrial membrane potential, and modulated apoptosis markers (Bax, Bcl-2, cleaved caspases).
• Rk1 blocked the PI3K/Akt pathway, and ROS/PI3K/Akt signaling mediated Rk1-induced apoptosis.

Conclusions:

• This study provides the first evidence of Rk1's anti-TNBC effects and mechanisms.
• Rk1 demonstrates significant anti-tumor activity against TNBC cells.
• Ginsenoside Rk1 represents a potential novel therapeutic agent for TNBC treatment.